German life sciences company Sartorius has announced the acquisition of BIA Separations, a Slovenian purification specialist in a deal worth €360 million.
Sartorius
Photo: Sartorius
BIA Separations develops and produces purification and analysis products for large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies.
The company's manufacturing scale purification technology is already used in the production of the first commercialised advanced therapeutics and it has a strong presence with such novel drug candidates in the clinical pipeline.
“Combining the teams and technologies of Sartorius and BIA will create a premium offering for the manufacturing of advanced therapies. The goal of our partnership is to enable such therapeutics to reach more patients faster and we are committed to continue delivering relevant innovations across the entire production chain,” commented Joachim Kreuzburg, CEO of Sartorius.
With strong double-digit sales growth expected over the coming years, BIA is forecasted to earn sales revenue of around €25 million in 2020.
Aleš Strancar, founder and CEO of BIA Separations, commented: “Partnering with Sartorius provides BIA Separations with a global sales and service network which will grow the sale of BIA Separations’ products by an order of magnitude in the coming years. I am especially excited that our combined R&D groups will result in one of the strongest development teams in bioprocessing worldwide which will rapidly increase the number of products under development while substantially reducing time to market.”
Back to Homepage
Back to Healthcare